Delaware | 1-11397 | 33-0628076 | ||
(State or other jurisdiction of | (Commission File Number) | (I.R.S Employer | ||
incorporation or organization) | Identification No.) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Q1 2006 | Q2 2006 | Q3 2006 | Q4 2006 | 2006 | ||||||||||||||||
Income (loss) from operations (GAAP) |
$ | 10,421 | $ | (5,066 | ) | $ | 28,244 | $ | 13,082 | $ | 46,681 | |||||||||
Depreciation and Amortization |
17,663 | 17,739 | 17,557 | 17,068 | 70,027 | |||||||||||||||
EBITDA (Non-GAAP) |
28,084 | 12,674 | 45,800 | 30,150 | 116,708 | |||||||||||||||
Adjustments: |
||||||||||||||||||||
Restructuring, asset impairments & dispositions |
26,171 | 24,827 | 14,562 | 23,056 | 88,616 | |||||||||||||||
Gain on Litigation Settlement |
(34,000 | ) | 0 | (17,550 | ) | 0 | (51,550 | ) | ||||||||||||
Adjusted EBITDA (Non-GAAP) |
$ | 20,255 | $ | 37,501 | $ | 42,812 | $ | 53,206 | $ | 153,774 | ||||||||||
Q1 2007 | Q2 2007 | Q3 2007 | Q4 2007 | 2007 | ||||||||||||||||
Income from operations (GAAP) |
$ | 21,283 | $ | 6,486 | $ | 10,038 | $ | 20,018 | $ | 57,825 | ||||||||||
Depreciation and Amortization |
17,862 | 18,105 | 17,957 | 17,710 | 71,634 | |||||||||||||||
EBITDA (Non-GAAP) |
39,145 | 24,591 | 27,995 | 37,728 | 129,459 | |||||||||||||||
Adjustments: |
||||||||||||||||||||
Restructuring, asset impairments & dispositions |
5,060 | 13,014 | 0 | 9,601 | 27,675 | |||||||||||||||
Adjusted EBITDA (Non-GAAP) |
$ | 44,205 | $ | 37,605 | $ | 27,995 | $ | 47,329 | $ | 157,134 | ||||||||||
Q1 2008 | Q2 2008 | Q3 2008 | Q4 2008 | 2008 | ||||||||||||||||
Income (loss) from operations (GAAP) |
$ | 17,356 | $ | (14,414 | ) | $ | 16,014 | $ | (152,449 | ) | $ | (133,493 | ) | |||||||
Depreciation and Amortization |
17,795 | 17,885 | 16,117 | 16,644 | 68,441 | |||||||||||||||
EBITDA (Non-GAAP) |
35,151 | 3,471 | 32,131 | (135,805 | ) | (65,052 | ) | |||||||||||||
Adjustments: |
||||||||||||||||||||
Acquired in-process research and development |
0 | 0 | 0 | 186,300 | 186,300 | |||||||||||||||
Restructuring, asset impairments & dispositions |
(13,190 | ) | 13,956 | 3,528 | 17,001 | 21,295 | ||||||||||||||
Adjusted EBITDA (Non-GAAP) |
$ | 21,961 | $ | 17,427 | $ | 35,659 | $ | 67,496 | $ | 142,543 | ||||||||||
Q1 2009 | ||||
Income from operations (GAAP) |
$ | 42,734 | ||
Depreciation and Amortization |
20,764 | |||
EBITDA (Non-GAAP) |
63,498 | |||
Adjustments: |
||||
Restructuring, asset impairments & dispositions |
1,211 | |||
Adjusted EBITDA (Non-GAAP) |
$ | 64,709 | ||
Valeant Pharmaceuticals International |
||||
Date: June 1, 2009 | By: | /s/ Peter J. Blott | ||
Peter J. Blott | ||||
Executive Vice President and Chief Financial Officer | ||||